

Haematologica
HAEMATOL/2019/223693
Version 3

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, and Michael Hallek

Disclosures: PC reports research funding from AbbVie, Acerta, F. Hoffmann-LaRoche, Gilead, GlaxoSmithKline, Janssen-Cilag and Novartis, honoraria for scientific talks by AbbVie, F. Hoffmann-LaRoche and Janssen-Cilag and for advisory boards by AbbVie, Acerta, AstraZeneca, Janssen-Cilag and Novartis, as well as travel grants by AbbVie, F. Hoffmann-LaRoche, Gilead, Janssen-Cilag and Mundipharma. JvT reports research funding from F. Hoffmann-LaRoche and Janssen-Cilag, honoraria for advisory boards by AbbVie, F. Hoffmann-LaRoche and Janssen-Cilag, as well as travel grants by Celgene, F. Hoffmann-LaRoche and Janssen-Cilag. JB reports honoraria and travel grants by F. Hoffmann-LaRoche. PL reports research funding from AbbVie, F. Hoffmann-LaRoche and Janssen-Cilag, honoraria Janssen-Cilag and travel grants from F. Hoffmann-LaRoche, Janssen-Cilag and Mundipharma. OA-S reports personal fees from F. Hoffmann-LaRoche, AbbVie and Gilead. WH reports research funding by MSD (Merck Sharp & Dohme) and Pfizer, honoraria for scientific talks by Alexion, Basilea, Gilead, MSD (Merck Sharp & Dohme) and Pfizer, advisory boards by Gilead Science, MSD, Pfizer, travel grants by Alexion, Astellas, Basilea, Gilead Science, MSD and Pfizer (all outside the submitted work). UVK reports honoraria for advisory boards by AbbVie, Amgen, F. Hoffmann-LaRoche, Gilead, Lilly and MSD. JD reports honoraria for scientific talks by F. Hoffmann-LaRoche, Janssen-Cilag, Celgene; advisory boards by AbbVie, Amgen, Bristol-Myers Squibb, Janssen-Cilag, Novartis, Gilead; travel grants by Celgene, F. Hoffmann-LaRoche, Gilead, Janssen-Cilag, and Mundipharma. ET reports travel grants from AbbVie, Celgene and Gilead. MHe reports honoraria for advisory boards by AbbVie and F. Hoffmann-LaRoche, and travel grants AbbVie and by F. Hoffmann-LaRoche. AMF reports research grants by Celgene and travel grants by AbbVie, F. Hoffmann-LaRoche and Mundipharma. KF reports travel grants from F. Hoffmann-LaRoche. KAK reports research support and honoraria for consultancy or advisory boards by AbbVie, F. Hoffmann-LaRoche and Mundipharma. SB reports grants and personal fees from AbbVie, F. Hoffmann-LaRoche and Janssen, grants from Celgene and Genentech, personal fees from Becton Dickinson and Novartis MR reports research funding from AbbVie, Amgen, F. Hoffmann-LaRoche and Gilead. MK reports honoraria for consultancy or advisory boards by AbbVie and F. Hoffmann-LaRoche. CMW reports research support, honoraria for consultancy or advisory boards and travel support by AbbVie, F. Hoffmann-LaRoche, Genentech, Gilead, GlaxoSmithKline, Janssen-Cilag, Mundipharma and Pharmacyclics. SS reports research support, honoraria for consultancy or advisory boards and travel support by AbbVie, Amgen, Celgene, F. Hoffmann-LaRoche, Genentech, Gilead, GlaxoSmithKline, Janssen-Cilag, Mundipharma, Novartis and Pharmacyclics. BE reports research support and honoraria for consultancy or advisory boards by AbbVie and F. Hoffmann-LaRoche. MHa Research support and honoraria: Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, AbbVie. NP, SR and MF report no conflict of interest.

Contributions: PC, JvT, JB, SB, BE and MH were responsible for the conception and design of the study; PC, JvT, SR, JB, MF, PL, NP, OA-S, AMF and KF were responsible for the trial management; PC, JvT, MF, PL, NP, OA-S, WH, UV-K, JD, ET, MHe, SS, SB, MR, MK, CMW, SS, BE and MH were responsible for the recruitment and treatment of patients; PC, JvT, SR, JB, MF, PL and NP had access to the raw data; PC, MF, PL and NP performed a central review of all clinical data; ET, KAK, SB, MR, MK and SS performed the laboratory analyses; SR and JB performed the statistical analysis. All authors interpreted the data; PC wrote the first draft of the manuscript and all authors approved the final manuscript.